Contact
searchSearch
HMP Global

Diabetic Macular Edema Topic Center

Featured

News
Balancing Medicare Advantage Denials for Patients With Diabetic Macular Edema
03/04/2024

Emry Lloyd

Emry Lloyd
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of...
03/04/2024
First Report Managed Care
News
Subthreshold Micropulse Laser Equivalent to Standard Laser Therapy for DME
01/10/2024
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser...
01/10/2024
First Report Managed Care
News
Response to First Anti-VEGF Injection for DME Predicts Long-term Effects of Therapy
11/21/2022
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial...
11/21/2022
First Report Managed Care
News
Retinal Thickness Lower With Intravitreal Steroids for Diabetic Macular Edema
11/09/2022
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the...
11/09/2022
First Report Managed Care
News
Treatment More Effective Than Laser Photocoagulation for Improving Diabetic Macular Edema
10/24/2022
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy...
10/24/2022
First Report Managed Care
News
Anti-VEGF Treatment Changes Aqueous Cytokine Levels in Patients With DME
10/21/2022
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the...
10/21/2022
First Report Managed Care
News
Cataract Surgery Outcomes Unaffected by Intravitreal Aflibercept for Diabetic Macular Edema
09/21/2022
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept,...
09/21/2022
First Report Managed Care
News
Intravitreal VEGF Inhibitors Associated With HbA1c Reduction for Patients With DME
09/14/2022
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact...
09/14/2022
First Report Managed Care
News
Preoperative Bevacizumab Benefits Patients With Diabetes With Vitreous Hemorrhage Without Tractional Detachment
06/02/2022
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood...
06/02/2022
First Report Managed Care
News
Study Compares 3 Drugs for Diabetic Macular Edema
02/19/2015
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs...
02/19/2015
First Report Managed Care
News
FDA Approves Drug for Diabetic Retinopathy with Diabetic Macular Edema
02/09/2015
The FDA approved ranibizumab injection 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema.
The FDA approved ranibizumab injection 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema.
The FDA approved ranibizumab...
02/09/2015
First Report Managed Care

Newsfeed

News
Balancing Medicare Advantage Denials for Patients With Diabetic Macular Edema
03/04/2024

Emry Lloyd

Emry Lloyd
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of...
03/04/2024
First Report Managed Care
News
Subthreshold Micropulse Laser Equivalent to Standard Laser Therapy for DME
01/10/2024
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser...
01/10/2024
First Report Managed Care
News
Response to First Anti-VEGF Injection for DME Predicts Long-term Effects of Therapy
11/21/2022
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial...
11/21/2022
First Report Managed Care
News
Retinal Thickness Lower With Intravitreal Steroids for Diabetic Macular Edema
11/09/2022
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the...
11/09/2022
First Report Managed Care
News
Treatment More Effective Than Laser Photocoagulation for Improving Diabetic Macular Edema
10/24/2022
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy...
10/24/2022
First Report Managed Care
News
Anti-VEGF Treatment Changes Aqueous Cytokine Levels in Patients With DME
10/21/2022
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the...
10/21/2022
First Report Managed Care
News
Cataract Surgery Outcomes Unaffected by Intravitreal Aflibercept for Diabetic Macular Edema
09/21/2022
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept,...
09/21/2022
First Report Managed Care
News
Intravitreal VEGF Inhibitors Associated With HbA1c Reduction for Patients With DME
09/14/2022
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact...
09/14/2022
First Report Managed Care
News
Preoperative Bevacizumab Benefits Patients With Diabetes With Vitreous Hemorrhage Without Tractional Detachment
06/02/2022
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood...
06/02/2022
First Report Managed Care
News
Study Compares 3 Drugs for Diabetic Macular Edema
02/19/2015
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs...
02/19/2015
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use